These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32928917)

  • 1. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.
    Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortés J; Ramsey SD; Briggs A; Hu P; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
    Cancer Res; 2020 Dec; 80(24):5427-5434. PubMed ID: 32928917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
    Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortes J; Ramsey S; Briggs A; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
    J Natl Compr Canc Netw; 2020 Aug; 18(8):1096-1104. PubMed ID: 32755985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
    Bagegni NA; Tao Y; Ademuyiwa FO
    PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis.
    Cunha MT; Gouveia MC; Neto FL; Testa L; Hoff PM; de Azambuja E; Bonadio RC
    Br J Cancer; 2024 Feb; 130(2):242-250. PubMed ID: 38012381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
    Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
    Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
    Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
    JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).
    Nekljudova V; Loibl S; von Minckwitz G; Schneeweiss A; Glück S; Crane R; Li H; Luo X
    Contemp Clin Trials; 2018 Aug; 71():194-198. PubMed ID: 29959104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
    Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
    Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
    Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
    Future Oncol; 2021 Oct; 17(29):3819-3831. PubMed ID: 34227400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
    Xia LY; Hu QL; Zhang J; Xu WY; Li XS
    World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
    Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
    Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
    Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Neoadjuvant
    Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
    In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.